昌吉哪个医院治宫颈糜烂(昌吉取环一共需要多少钱) (今日更新中)

BEIJING, Aug. 12 (Xinhuanet) -- The risk of developing coronary heart disease is 25 percent higher for women smokers compared with men, according to a study published in the British medical journal "The Lancet".The authors say this could be due to the physiological differences between the sexes with cigarette smoke toxins having a more potent effect on women.The study by Dr Rachel R Huxley from the University of Minnesota and Dr Mark Woodward from Johns Hopkins University involved a meta-analysis of around four million individuals and 67,000 coronary heart disease events from 86 studies.The researchers found that the pooled adjusted female-to-male relative risk ratio (RRR) of smoking compared with not smoking for coronary heart disease (CHD) was 1.25 (25 percent) higher for women.This RRR increased by 2 percent for every additional year of follow-up, meaning that the longer a woman smokes, the higher her risk of developing CHD becomes compared with a man who has smoked the same length of time.The authors say, "The finding lends support to the idea of a pathophysiological basis for the sex difference. For example, women might extract a greater quantity of carcinogens and other toxic agents from the same number of cigarettes than men. This occurrence could explain why women who smoke have double the risk of lung cancer compared with their male counterparts."Worldwide, there are 1.1 billion smokers, of whom a fifth are women.According to the Tobacco Atlas, India, with around a crore female smokers, ranks third in the top 20 female smoking populations across the globe, only the U.S. with 2.3 crore female smokers and China with 1.3 crore female smokers, are worse off.

LOS ANGELES, July 19 (Xinhua) -- Obesity prevalence was 30 percent or higher in 12 states of the United States last year, compared to nine states in 2009, the Centers for Disease Control and Prevention (CDC) said on Tuesday.In 2000, no states in the country had obesity rates that high, and now obesity is a problem in all 50 states, the agency said in a report based on telephone interviews with 400,000 people.Obesity rates vary by region, led by the South at 29.4 percent, followed by the Midwest at 28.7 percent, the Northeast at 24.9 percent, and the West at 24.1 percent, the report said.Mississippi had the nation's highest obesity prevalence at 34 percent, and Colorado the lowest at 21 percent, according to the report.Alabama, Arkansas, Kentucky, Louisiana, Michigan, Mississippi, Missouri, Oklahoma, South Carolina, Tennessee, Texas, and West Virginia all had obesity rates of 30 percent or higher in 2010, said the report.No state met the federal Healthy People 2010 goal of a 15 percent obesity rate. In fact, no state had a rate lower than 20 percent, the CDC said.Obesity rates have kept rising despite a steady drumbeat of warnings that obesity causes serious health problems and increases the risk of premature death, CDC officials said.An adult is considered obese if he or she has a body mass index (BMI) of 30 or greater.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

SAN FRANCISCO, Aug. 15 (Xinhua) --- Google Inc. on Monday announced that it has agreed to buy Motorola Mobility Holdings Inc. for about 12. 5 billion U.S. dollars, the largest purchase for the Internet search giant that will allow it to compete more directly with other mobile phone makers.Google said that it will acquire Motorola Mobility for 40 dollars per share in cash, or a total of about 12.5 billion dollars, a premium of 63 percent to the closing price of Motorola Mobility shares last Friday.The transaction was unanimously approved by the boards of directors of both companies and is expected to close by the end of 2011 or early 2012, subject to regulatory approvals and other closing conditions.Google noted that the acquisition of Motorola Mobility, a dedicated partner of its Android mobile operating system, will enhance competition in mobile computing.Motorola Mobility will remain a licensee of Android and Android will remain open, Google said, adding that it will run Motorola Mobility as a separate business."Motorola Mobility's total commitment to Android has created a natural fit for our two companies. Together, we will create amazing user experiences that supercharge the entire Android ecosystem for the benefit of consumers, partners and developers," Larry Page, Google's chief executive officer (CEO), said in a statement."We have shared a productive partnership with Google to advance the Android platform, and now through this combination we will be able to do even more to innovate and deliver outstanding mobility solutions across our mobile devices and home businesses," said Sanjay Jha, CEO of Motorola Mobility.

WELLINGTON, July 26 (Xinhua) -- Children born early are less likely to develop serious behavioral problems than previously thought because previous studies may have relied too much on the opinions of "sensitive" parents, according to a controversial New Zealand research.The study by the Child Development Research Group at the University of Canterbury looked at the emotional and behavioral adjustment of children born very preterm (VPT).It showed that by age 6 children born very preterm (less than 33 weeks) were at an increased risk of emotional and attentional problems when compared with their full term peers, said a statement from the university.However, the findings suggested the risks may be lower than previous studies had suggested, because previous studies primarily relied on parents to provide information on their children's conditions, said lead author Samudragupta Bora."While parents are an important source of information about their child, it is also important to gather information from other significant people in the child's life such as their classroom teacher," said Bora.Bora and other members of the research team, found that parents reported higher rates of emotional and attention problems in their children than teachers did."Having a baby born prematurely is an extremely stressful experience for parents. During their baby's stay in the neonatal unit most parents will have been alerted to the possibility of their child developing problems such as behavioral difficulties in the future due to being born too early. Therefore, very understandably, many parents of these children are very sensitive to the possibility of developmental problems," he said."The use of multiple informants - parents, teachers and clinical observation - to assess VPT children's well-being is important to minimize the effects of report source bias and the over or under-identification of adjustment problems in children born VPT," said Bora."This is controversial because it shows that reliance on parents or teachers alone can lead to data validity issues."Although children born VPT were at higher risk of showing emotional and attentional problems, the risks of more severe problems were relatively modest, said Bora.The findings have been published the Journal of Paediatrics and Child Health.

来源：资阳报